1. Impaired Renal Function May Not Negate the Efficacy of Tolvaptan in the Treatment of Cirrhotic Patients with Refractory Ascites
- Author
-
Tatehiro Kagawa, Kazuya Anzai, Kota Tsuruya, Tetsuya Mine, Ryuzo Deguchi, Yoshitaka Arase, Hirohiko Sato, Koichi Shiraishi, Erika Teramura, and Shunji Hirose
- Subjects
Adult ,Liver Cirrhosis ,Male ,medicine.medical_specialty ,Cirrhosis ,Tolvaptan ,Renal function ,Urine ,030204 cardiovascular system & hematology ,urologic and male genital diseases ,030226 pharmacology & pharmacy ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Ascites ,medicine ,Humans ,Pharmacology (medical) ,Original Research Article ,Renal Insufficiency, Chronic ,Adverse effect ,Aged ,Retrospective Studies ,Aged, 80 and over ,business.industry ,Retrospective cohort study ,General Medicine ,Middle Aged ,medicine.disease ,female genital diseases and pregnancy complications ,Female ,medicine.symptom ,business ,Antidiuretic Hormone Receptor Antagonists ,Kidney disease ,medicine.drug ,Glomerular Filtration Rate - Abstract
Background and Objective Tolvaptan, an oral vasopressin V2 receptor antagonist, has been widely used for the treatment of patients with cirrhosis and ascites. However, its efficacy in patients with renal dysfunction remains unknown. The objective of this study was to investigate the efficacy and safety of tolvaptan in patients with decompensated cirrhosis and severe chronic kidney disease (s-CKD). Methods We studied 43 patients with liver cirrhosis who received tolvaptan (7.5 mg/day) for refractory ascites. s-CKD was defined as an estimated glomerular filtration rate (eGFR)
- Published
- 2018